semaglutide wesley chapel GLP-1 Weight Loss Injections semaglutide weight loss wesley chapel

It randomised 156 participants with early disease to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout

Mounjaro and Zepbound (Tirzepatide) Tirzepatide is a dual-acting medication that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

Wang R, Dineley KT, Sweatt JD, Zheng H

Research Background & Mechanistic Focus Current research use centers on single-pathway incretin receptor signaling and comparative peptide-pathway models, comparative presentation or formulation behavior where applicable, and controlled experimental models designed to evaluate compound-specific signaling activity within non-clinical laboratory systems

However, some providers may start at 2 mg if the patient has previously tolerated GLP-1 medications well